{"entity":{"id":"ceacam5-expression","kind":"biomarker","name":"CEACAM5 expression","aka":["CEACAM5","CEACAM5-positive","CEACAM5 high","CEA cell adhesion molecule 5 expression"],"tldr":"CEACAM5 is the cell-surface form of the tumour marker CEA, high on many lung and bowel cancers. Tusamitamab ravtansine was tested in CEACAM5-high lung cancer but failed its phase 3 and no approval exists.","summary":"The CARMEN-LC03 trial (NCT04154956) selected non-squamous NSCLC with CEACAM5 expression at 2+ intensity in 50 percent or more of tumour cells by IHC; it did not meet its endpoints and development stopped in 2023. Newer CEACAM5 ADCs and bispecifics are in early trials with similar IHC gates. No label names CEACAM5.","asOf":"2026-09-23","links":[{"label":"ClinicalTrials.gov NCT04154956 (CARMEN-LC03)","url":"https://clinicaltrials.gov/study/NCT04154956"}],"tags":["biomarker","surface-antigen","no-threshold"],"related":["trop2-expression"],"cancers":["nsclc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["tusamitamab-ravtansine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"ceacam5","measurement":"ihc-score","scoringRule":{"text":"The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.","quote":"CARMEN-LC03: tusamitamab ravtansine versus docetaxel in CEACAM5-positive non-squamous NSCLC","source":"https://clinicaltrials.gov/study/NCT04154956","sourceLabel":"ClinicalTrials.gov NCT04154956 (CARMEN-LC03)"},"thresholds":[],"definedBy":{"label":"CARMEN-LC03 (NCT04154956): CEACAM5 IHC 2+ in >= 50% of tumour cells","url":"https://clinicaltrials.gov/study/NCT04154956"},"tests":[],"assays":[],"companionDiagnostics":[],"forPatient":"CEACAM5 staining is not a routine test and no approved drug depends on it; the one late-stage antibody-drug conjugate aimed at it did not succeed. Trials of newer CEACAM5 drugs may use the stain to select patients."},"route":"/biomarkers/ceacam5-expression/","neighbours":{"biomarker":[{"id":"trop2-expression","kind":"biomarker","name":"TROP2 expression","route":"/biomarkers/trop2-expression/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/"}],"target":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/"}]}}